<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1551152/000155115223000011/abbv-20221231.htm>Download 10-K Annual Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1551152/000155115223000011/0001551152-23-000011-index.htm>Original filing index</a>
                    </div>

XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Abbvie Inc

AbbVie Delivers Strong 2022 Financial Results
Current Analysis:
AbbVie Inc. delivered strong financial results in 2022, with worldwide net revenues increasing by 3% on a reported basis and 5% on a constant currency basis, reflecting growth across its immunology, neuroscience and aesthetics portfolios. AbbVie’s financial performance in 2022 included delivering worldwide net revenues of $58.1 billion, operating earnings of $18.1 billion, diluted earnings per share of $6.63 and cash flows from operations of $24.9 billion. Additionally, financial results reflected continued funding to support all stages of AbbVie’s pipeline assets and continued investment in AbbVie’s on-market brands. Following the closing of the Allergan acquisition in 2020, AbbVie also implemented an integration plan to reduce costs and optimize the organization, resulting in $2.5 billion of annual cost synergies in 2022.

Forward-Looking Analysis:
In the future, AbbVie expects to be focused on delivering strong financial results, maximizing the benefits of the Allergan acquisition, advancing and investing in its pipeline and returning value to shareholders while ensuring a strong, sustainable growth business over the long term. AbbVie is also keeping an eye on recent global events, such as the military conflict between Russia and Ukraine and the Coronavirus Disease 2019 (COVID-19) pandemic, as they may impact its operations and results of operations. As such, AbbVie continues to closely manage manufacturing and supply chain resources around the world to ensure that patients continue to receive an uninterrupted supply of their medicines. Additionally, AbbVie is continuing to invest in its pipeline and focus on continuous innovation in areas of

Announcement: ABBV 10-K Annual Report

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1364742/000130655023008705/us00287y1091_021523.txt>Download SC 13G/A Special Filing</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1551152/000130655023008705/0001306550-23-008705-index.htm>Original filing index</a>
                    </div>

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

Announcement: ABBV SC 13G/A Statement of acquisition of beneficial ownership by individuals - amendment

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/102909/000110465923015040/tv0002-abbvieinc.htm>Download SC 13G/A Special Filing</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1551152/000110465923015040/0001104659-23-015040-index.htm>Original filing index</a>
                    </div>

<div style="margin-bottom: 10px;">
                      <a href=https://www.sec.gov/Archives/edgar/data/1551152/000155115223000006/abbv-20230209.htm>Download 8-K Special Filing Report</a>
                    </div>
                    <div>
                      <a href=https://www.sec.gov/Archives/edgar/data/1551152/000155115223000006/0001551152-23-000006-index.htm>Original filing index</a>
                    </div>

Form 8-K - Current report - Item 2.02 Item 9.01

Analyst Summary: AbbVie announced their Q4 and full-year 2022 financial results, with revenue increasing to $63.1 billion on a GAAP basis, indicating a 2.0% YoY increase. The company attributed this success to its diverse portfolio of growth products, robust innovative pipeline, and strong execution culture. The company is confident its solid foundation will absorb the loss of exclusivity of U.S. Humira, drive top-line growth by 2025, and result in strong financial performance over the long term. AbbVie reported a gross margin ratio of 72.4% in Q4, and the adjusted gross margin ratio was 86.0%. CEO Richard A. Gonzalez stated that "2022 was another highly productive year capping a decade of outstanding performance," and AbbVie is looking forward to returning to strong top-line growth by 2025. Several key pipeline developments were announced in collaboration with other companies, including the approval by the European Commission of Skyrizi as the first specific interleukin-23 inhibitor for the treatment of adults with moderately-to-severely active Crohn's disease, and the initiation of a worldwide collaboration and option agreement with Immunome for the discovery of up to 10 novel antibody-target pairs for three specified tumour types. The company is not providing revenue or EPS guidance for 2023 at this time.

Announcement: ABBV 8-K Special Filing

<div style="margin-bottom: 10px;">
                          <a href=https://www.sec.gov/Archives/edgar/data/1551152/000110465923002452/tm232769d1_8k.htm>Download 8-K Special Filing Report</a>
                        </div>
                        <div>
                          <a href=https://www.sec.gov/Archives/edgar/data/1551152/000110465923002452/0001104659-23-002452-index.htm>Original filing index</a>
                        </div>

XBRL TAXONOMY EXTENSION DEFINITION LINKBASE

XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE

Form 8-K - Current report - Item 7.01 Item 9.01

<div style="margin-bottom: 10px;">
                          <a href=https://www.sec.gov/Archives/edgar/data/1551152/000155115223000004/abbv-20230106.htm>Download 8-K Special Filing Report</a>
                        </div>
                        <div>
                          <a href=https://www.sec.gov/Archives/edgar/data/1551152/000155115223000004/0001551152-23-000004-index.htm>Original filing index</a>
                        </div>

Analyst Summary: AbbVie Inc., a public company, recently released their latest financial results, which included guidance that incorporates the impact of acquired IPR&D (in-process research and development) and milestones expense. The company's CEO, Richard A. Gonzalez, stated: "Based on our strong fourth-quarter performance and confidence in the continued growth of our key products, we are pleased to provide robust guidance for 2023, which includes a full-year contribution from Allergan." Notably, the company expects adjusted earnings per share to grow at a compound annual growth rate (CAGR) of 10% through 2025, with growth anticipated in all therapeutic areas. Additionally, AbbVie may undertake or pursue strategic actions, including business combinations, divestitures, or acquisitions, which may impact their financial performance. Investors should note that forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, as discussed in the company's recent SEC filings.